Exploratory results from the CheckMate 214 trialdoi:10.1038/s41585-021-00553-2Clinical trialsRenal cell carcinomaMedicine/Public HealthgeneralUrologyMaria Chiara Masone
To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). Methods Patients with aRCC with ...
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-2502. doi:10.1016/S0140-6736(17)31046-2PubMedGoogle ScholarCrossref 6. Zhu AX, Finn RS, ...
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma.
PFS: The combination doubled median PFS (17.0 months vs. 8.3 months, respectively; HR 0.52; 95% CI: 0.43 to 0.64), the trial’s primary endpoint, compared to sunitinib. ORR: Nearly twice as many patients responded toOPDIVOin combination withCABOMETYXvs. sunitinib (54.8% ...
The trial did not achieve statistical significance for its primary endpoint of overall survival (OS) per the pre-specified analysis (HR=0.85 [95% CI: 0.72-1.02]; p=0.0752). No new safety signals were observe...
[102]. These results expand on the findings seen in a similar trial that focused on the PD-1 inhibitor nivolumab monotherapy in non-squamous NSCLC BrM, which confirmed that while PD-1 inhibitors are active and show some benefit in OS these patients, IT monotherapy does not show the same ...
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Bristol-Myers Squibb. AB El-Khoueiry,B Sangro,T Yau,... - 《Lancet》 被引量: 255发表: 2017年 ...
We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allow...
Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial. This is a modal window. This video is either unavailable or not supported in this browserError Code:...